English

• 5 Oct, 2023
  Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ)
• 5 Oct, 2023
  Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad
• 31 Jul, 2023
  Spago Nanomedical interim report January-June 2023
• 28 Jun, 2023
  Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02
• 13 Jun, 2023
  Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board
• 23 May, 2023
  Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study
• 10 May, 2023
  Bulletin from the 2023 Annual General Meeting of Spago Nanomedical AB
• 9 May, 2023
  Spago Nanomedical interim report January-March 2023
• 4 May, 2023
  Presentation of Spago Nanomedical’s clinical phase IIa study in endometriosis at the 15th World Congress of Endometriosis
• 5 Apr, 2023
  Notice to Annual General Meeting of Spago Nanomedical AB (publ)